Bausch & Lomb Zylet approved
Executive Summary
Bausch & Lomb's combination ophthalmic Zylet clears FDA Dec. 14 for treatment of "steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists." B&L will launch Zylet (loteprednol 0.5%/tobramycin 0.3%) in the first quarter of 2005. The product will be promoted by reps who had been detailing Optivar, which is being taken in-house by MedPointe. B&L will conduct a Phase IV study of Zylet in 60 children up to six years of age. Loteprednol developer Pharmos expects to receive a milestone payment from B&L in the next six months...
You may also be interested in...
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.